StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)

Close on Nov 18, 2026Market cap $291.16MP/E –Yield –

SAB Biotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

SAB Biotherapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$34.63M. For fiscal 2025 it was -$45.71M. The highest annual figure on record is -$2.73M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.71M–
FY2024Dec 31, 2024-$34.63M–
FY2023Dec 31, 2023-$25.32M–
FY2022Dec 31, 2022-$25.63M–
FY2021Dec 31, 2021-$8.96M–
FY2020Dec 31, 2020-$2.73M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.43M–
Q1 FY2026Mar 31, 2026-$15.25M–
Q4 FY2024Dec 31, 2024-$9.59M–
Q3 FY2024Sep 30, 2024-$6.39M–
Q2 FY2024Jun 30, 2024-$7.77M–
Q1 FY2024Mar 31, 2024-$10.88M–
Q4 FY2023Dec 31, 2023-$13.51M–
Q3 FY2023Sep 30, 2023-$5.25M–
Q2 FY2023Jun 30, 2023-$4.92M–
Q1 FY2023Mar 31, 2023-$1.63M–
Q4 FY2022Dec 31, 2022-$1.67M–
Q3 FY2022Sep 30, 2022-$8.00M-1504.7%
Q2 FY2022Jun 30, 2022-$5.06M–
Q1 FY2022Mar 31, 2022-$10.90M-244.1%
Q4 FY2021Dec 31, 2021-$7.24M–
Q3 FY2021Sep 30, 2021$569.32K–
Q2 FY2021Jun 30, 2021-$9.85M–
Q1 FY2021Mar 31, 2021$7.56M–

More SAB Biotherapeutics figures

See a number that looks wrong?